# CytomX Therapeutics (CTMX) — News

CTMX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ctmx/news

## Recent headlines

- [Regeneron exec says co eligible to receive $1 bln in potential milestone payment with the start of the first late-stage trial as part of the deal -Conf call](https://www.ainvest.com/news/regeneron-exec-eligible-receive-1-bln-potential-milestone-payment-start-late-stage-trial-part-deal-conf-call-2610) — AInvest Wire, Oct 1, 2026
  Regeneron Pharmaceuticals, Inc. (REGN) is positioned to receive up to $1 billion in potential milestone payments as part of its expanded collaboration with Sanofi, according to remarks made during a conference call. The companies announced the expansion of their longstanding antibody collaboration,…
- [Cytomx TherA gets FDA fast track designation for Varseta-M](https://www.ainvest.com/news/cytomx-thera-fda-fast-track-designation-varseta-2608) — AInvest Wire, Aug 27, 2026
  CytomX Therapeutics has announced plans for an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational therapy Varsetatug masetecan (Varseta-M) for the treatment of late-line metastatic colorectal cancer (mCRC). The company aims to align with the FDA on the…
- [CytomX Therapeutics Q2 EPS USD -0.09](https://www.ainvest.com/news/cytomx-therapeutics-q2-eps-usd-0-09-2608) — AInvest Wire, Aug 6, 2026
  CytomX Therapeutics, Inc. (Nasdaq: CTMX) reported a net loss per share of -$0.09 for the second quarter of 2026, reflecting continued investment in its clinical-stage pipeline of PROBODY® therapeutics. The company’s Q2 2026 financial results showed a net loss of $18.2 million, or -$0.10 per share…
- [Cytomx 2Q revenue $1.42M, estimate $6.93M](https://www.ainvest.com/news/cytomx-2q-revenue-1-42m-estimate-6-93m-2608) — AInvest Wire, Aug 6, 2026
  CytomX Therapeutics (NASDAQ: CTMX) reported second-quarter 2026 revenue of $1.42 million, significantly below the estimated $6.93 million . The company’s earnings per share (EPS) for the quarter was -$0.10, surpassing the consensus estimate of -$0.14 by $0.04. This performance reflects a continued…
- [CytomX Therapeutics announces appointment of Charles Fuchs, M.D., M.P.H., to the board of directors](https://www.ainvest.com/news/cytomx-therapeutics-announces-appointment-charles-fuchs-board-directors-2607) — AInvest Wire, Jul 27, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).